Humana Long Climb: Navigating The 4-STAR Recovery And The J-Curve
Humana faces severe headwinds from rising medical costs and a dramatic drop in 4-STAR Medicare Advantage membership, pressuring margins and profitability. Management is implementing STAR mitigation efforts and aggressive CenterWell and Medicaid expansion, targeting a turnaround by bonus year 2028. Despite near-term margin compression and operational risk, my DCF-based valuation of $330 per share suggests HUM is undervalued and presents a buying opportunity.
Is the Options Market Predicting a Spike in Humana Stock?
Investors need to pay close attention to Humana stock based on the movements in the options market lately.
Humana Incurs Q4 Loss, Revenues Up Y/Y on CenterWell Unit Strength
HUM incurs a wider year-over-year loss in Q4 due to rising costs, weaker investment income and membership declines. Yet, revenues climb 12% on CenterWell strength.
Humana (HUM) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana Reports $796 Million Loss As Ongoing Costs Dog Health Insurers
Humana Wednesday reported a $796 million fourth quarter loss as the health insurer continued to grapple with high medical costs of its Medicare Advantage health plan members.
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
Humana (HUM) came out with a quarterly loss of $3.96 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $2.16 per share a year ago.
Will Declining Medical Membership Affect Humana's Q4 Earnings?
HUM heads into Q4 with declining medical membership and rising costs, clouding earnings despite expectations for solid revenue growth.
Ahead of Humana (HUM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Humana (HUM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Humana Unveils AI-Powered Agent Assist Built With Google Cloud
Health insurance company Humana launched Agent Assist, a new artificial intelligence-driven support tool developed with Google Cloud, according to a Tuesday (Feb. 3) press release. The tool is designed to help member advocates deliver faster, more personalized responses to health benefits and eligibility questions, the release said.
Is Humana Stock Now A Value Trap At $200?
Humana stock plummeted 21% on January 27. Humana is a "pure play" on Medicare Advantage—around 85% of their operations.
Humana Partners With Atlas to Enhance Cancer Care for Seniors
HUM teams up with Atlas Oncology to make a cancer care model available for its eligible MA members in TN and MS starting in 2026.
Why Humana Deserves Patience Now: Too Early to Buy, Too Risky to Sell
HUM sits at a crossroads as Medicare Advantage pressures cap near-term upside, but resilience versus peers argues for patience, not panic.
